In our previous study, we developed a novel cationic
liposome, which was modified with truncated human
basic fibroblast growth factor (tbFGF)
peptide. This tbFGF-mediated cationic
liposome could deliver chemotherapeutic agents or gene specifically to FGFRs on
tumors and obtained higher transfection efficiency than plain cationic
liposomes. In order to investigate whether this novel cationic
liposome could achieve a synergistic/combined anti-
tumor effect as a co-delivery system, we simultaneously delivered
doxorubicin (DOX) and the plasmid encoding the phosphorylation-defective mouse
survivin threonine 34-->
alanine mutant (Msurvivin T34A plasmid) to the same cells through this cationic
liposome. As a result, an enhanced antiproliferative activity in vitro has been achieved by delivering DOX and
DNA simultaneously to the
Lewis lung carcinoma cells (LLC) using this
liposome. The concentration of DOX in the co-delivery system which caused 50% killing was nearly 3-fold lower than that of the free DOX. Furthermore, the co-delivery system suppressed
tumor growth more efficiently than either DOX or the Msurvivin T34A plasmid alone in the
Lewis lung carcinoma-bearing C57BL/6 mice. After 18 days of treatment with the co-delivery system, the average
tumor volume in mice was decreased by 80%, which was higher than liposomal DOX (70%, P<0.05) and Msurvivin T34A plasmid (41%, P<0.01). The co-delivery system also caused 15 days delay of
tumor growth, which was longer than the other treatment groups. In conclusion, this novel cationic
liposome is an efficient vector to simultaneously deliver drugs and
DNA to the same cells in vitro and in vivo.